Allergan PLC, a global biopharmaceutical company, recently concluded its $2.9 billion acquisition of LifeCell Corp., a business that develops regenerative medicine.
"The completion of the LifeCell acquisition is an important milestone for Allergan, serving as our entry point into regenerative medicine as we continue to add to our world-class aesthetic and plastic surgery business," Allergan Chairman and CEO Brent Saunders said in a statement. "The combination of LifeCell's novel regenerative medicine products coupled with Allergan's innovative medical aesthetics and plastic surgery portfolio creates a more complete product offering for plastic surgeons globally."
LifeCell’s portfolio includes Acellular Dermal Matrices, which are used in breast reconstruction procedures; Alloderm, which is used in breast reconstruction post-masectomy; and Revolve, which is used in plastic and reconstructive procedures. Additionally, LifeCell markets Strattice, which is used in the surgical repair of damaged or ruptured soft tissue in abdominal walls.
Allergan acquired this commercial portfolio, as well as LifeCell’s New-Jersey-based manufacturing capabilities and its R&D operations. The acquisition of LifeCell adds to Allergan’s leading portfolio of medical aesthetic products, breast implants and tissue expanders.
Alerts Sign-up